MedTrace Logo

Effectiveness of Low Volume Versus High Volume of Local Anesthetic in Ultrasound Guided Combined Supraclavicular and Interscalene Block for Upper Limb Surgery

NCT07028957 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-07-23

No results posted yet for this study

Summary

The aim of this study is to evaluate the effectiveness of low versus high volumes of local anesthetic in ultrasound-guided combined supraclavicular block (SCB) and interscalene block (ISB) for upper limb surgery. This randomized, controlled trial will assess the analgesic effectiveness of low-volume local anesthetic in these blocks.

We hypothesize that a low volume will provide similar analgesic effects to a high volume, with fewer complications. The study will involve 40 adult ASA I and ASA II patients undergoing upper limb surgery, divided into two groups: Group A (low volume) and Group B (high volume).

The primary outcome will compare intraoperative and postoperative analgesic effects of different volumes.

The secondary outcome will evaluate complications related to local anesthetics (toxicity) and injection techniques (e.g., phrenic nerve palsy, pneumothorax, hematoma).

Conditions

  • Analgesia, Postoperative
  • Complications of Treatment

Interventions

PROCEDURE

Group A; Low volume local anesthetic in Ultrasound guided combined Supraclavicular and Interscalene block for Upper limb surgery

Group A; will receive ultrasound guided combined Supraclavicular Block (SCB) with 7-10 ml (3.5-5 ml bupivacaine 0.5% plus 3.5-5 ml lidocaine 2%) and Interscalene Block (ISB) with 7-10 ml (3.5-5 ml bupivacaine 0.5% plus 3.5-5 ml lidocaine 2%).

PROCEDURE

Group B; High volume local anesthetics (30-40ml) ultrasound guided combined Supraclavicular Block (SCB) and Interscalene Block (ISB)

Group B; High volume local anesthetics in ultrasound guided combined Supraclavicular Block (SCB) with 15-20 ml (7.5-10ml bupivacaine 0.5% plus 7.5-10 ml lidocaine 2%) and Interscalene Block (ISB) with 15-20 ml (7.5-10 ml bupivacaine 0.5% plus 7.5-10 ml lidocaine 2%).

Sponsors & Collaborators

  • Misr University for Science and Technology

    lead OTHER

Principal Investigators

  • Hossam S. El Din El Ashmawi, Prof. of anesthesia and pain · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-30
Primary Completion
2026-01-31
Completion
2026-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07028957 on ClinicalTrials.gov